CAS 19171-19-8
:Pomalidomid
- 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-
- 2-(2,6-Dioxopiperidin-3-yl)-4-amino-isoindole-1,3-dione
- 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide
- 4-Amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione
- 4-Amino-2-(2,6-dioxo-3-piperidinyl)isoindole-1,3-dione
- 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
- 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
- 4-Amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
- 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione
- Actimid
- Cc 4047
- Imnovid
- Phthalimide, 3-amino-N-(2,6-dioxo-3-piperidyl)-
- Weitere Synonyme anzeigen
Pomalidomide
CAS:Formel:C13H11N3O4Reinheit:>98.0%(HPLC)Farbe und Form:White to Yellow to Green powder to crystalineMolekulargewicht:273.254-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
CAS:Formel:C13H11N3O4Reinheit:98%Farbe und Form:SolidMolekulargewicht:273.2441Pomalidomide
CAS:Pomalidomide (CC-4047) is an anti-angiogenic and immunomodulatory agent. Pomalidomide is a ligand for CRBN. Cost-effective and quality-assured.Formel:C13H11N3O4Reinheit:98.8% - >99.99%Farbe und Form:SolidMolekulargewicht:273.24Pomalidomide
CAS:Formel:C13H11N3O4Reinheit:≥ 98.5%Farbe und Form:Yellow to green powderMolekulargewicht:273.24Pomalidomide
CAS:Applications Pomalidomide is a thalidomide derivative, a potent inhibitor of TNF-α production. It is an antiinflammatory and antitumor agent used in the treatment of multiple myeloma.
References Ruchelman, A. et al.: Bioorg. Med. Chem. Lett., 23, 360 (2013); Latif, T. et al.: Exp. Hematol. Oncol., 1, 27 (2012); Man, H. et al.: Bioorg. Med. Chem. Lett., 13, 3415 (2003); Muller, G. et al.: Bioorg. Med. Chem. Lett., 9, 1625 (1999)Formel:C13H11N3O4Farbe und Form:YellowMolekulargewicht:273.24Pomalidomide - Bio-X ™
CAS:Kontrolliertes ProduktPomalidomide is an immunomodulatory agent that inhibits transcriptional regulation by interacting with the pomalidomide-binding protein, which prevents its interaction with RNA polymerase II and thereby prevents DNA transcription. The study with U266 cells demonstrated that pomalidomide targets CRBN, part of an E3 ligase complex, and inhibits its autoubiquinitation and supresses a critical gene (IRF4, interferon regulatory factor 4) for myeloma cell growth with concentrations up to 10 μM. In vitro assays have shown that pomalidomide has inhibitory effects on cell signaling pathways, such as the NF-κB pathway. Pomalidomide also decreases the production of proinflammatory cytokines, such as TNFα and IL-1β, by inhibiting their synthesis or their release from activated monocytes. Recently, the promoting effect of pomalidomide, as its analog lenalidomide, on erythropoiesis (production of red blood cells) has been investigated, demonstrating positive results for its use as a potential new therapy agent for β-hemoglobinopathies. Pomalidomide is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.Formel:C13H11N3O4Reinheit:Min. 99 Area-%Farbe und Form:PowderMolekulargewicht:273.24 g/molPomalidomide
CAS:Kontrolliertes ProduktPomalidomide is an immunomodulatory agent that inhibits transcriptional regulation by interacting with the pomalidomide-binding protein, which prevents its interaction with RNA polymerase II and thereby prevents DNA transcription. The study with U266 cells demonstrated that pomalidomide targets CRBN, part of an E3 ligase complex, and inhibits its autoubiquinitation and supresses a critical gene (IRF4, interferon regulatory factor 4) for myeloma cell growth with concentrations up to 10 μM.In vitro assays have shown that pomalidomide has inhibitory effects on cell signaling pathways, such as the NF-κB pathway. Pomalidomide also decreases the production of proinflammatory cytokines, such as TNFα and IL-1β, by inhibiting their synthesis or their release from activated monocytes. Recently, the promoting effect of pomalidomide, as its analog lenalidomide, on erythropoiesis (production of red blood cells) has been investigated, demonstrating positive results for its use as a potential new therapy agent for β-hemoglobinopathies.Formel:C13H11N3O4Reinheit:Min. 98 Area-%Farbe und Form:Yellow PowderMolekulargewicht:273.24 g/mol4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
CAS:Formel:C13H11N3O4Reinheit:98%Farbe und Form:SolidMolekulargewicht:273.248Pomalidomide-d5
CAS:Kontrolliertes ProduktApplications Pomalidomide-d5 is the labeled analogue of Pomalidomide (P688200), a thalidomide derivative, a potent inhibitor of TNF-α production. It is an antiinflammatory and antitumor agent used in the treatment of multiple myeloma.
References Ruchelman, A. et al.: Bioorg. Med. Chem. Lett., 23, 360 (2013); Latif, T. et al.: Exp. Hematol. Oncol., 1, 27 (2012); Man, H. et al.: Bioorg. Med. Chem. Lett., 13, 3415 (2003); Muller, G. et al.: Bioorg. Med. Chem. Lett., 9, 1625 (1999)Formel:C13D5H6N3O4Farbe und Form:NeatMolekulargewicht:278.27Pomalidomide-d2 (Major)
CAS:Kontrolliertes ProduktFormel:C13D2H9N3O4Farbe und Form:NeatMolekulargewicht:275.26









